Ieq Capital LLC grew its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 465.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,993 shares of the medical research company's stock after purchasing an additional 22,222 shares during the quarter. Ieq Capital LLC's holdings in Exact Sciences were worth $1,517,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Huntington National Bank boosted its holdings in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after acquiring an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in Exact Sciences during the third quarter worth $34,000. Capital Performance Advisors LLP purchased a new position in Exact Sciences in the third quarter worth $35,000. Asset Planning Inc acquired a new stake in Exact Sciences in the fourth quarter valued at $40,000. Finally, Modus Advisors LLC purchased a new stake in shares of Exact Sciences during the 4th quarter worth $43,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts recently commented on EXAS shares. Robert W. Baird reduced their price objective on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Scotiabank lifted their price target on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Monday. Barclays lowered their price target on Exact Sciences from $70.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Stifel Nicolaus dropped their price objective on Exact Sciences from $82.00 to $67.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Exact Sciences currently has an average rating of "Moderate Buy" and an average price target of $71.94.
Get Our Latest Stock Report on Exact Sciences
Exact Sciences Trading Down 0.9 %
EXAS traded down $0.41 during trading on Friday, hitting $47.41. The company's stock had a trading volume of 3,106,394 shares, compared to its average volume of 2,339,565. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The firm's 50 day moving average price is $54.17 and its 200-day moving average price is $59.79. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The stock has a market cap of $8.81 billion, a PE ratio of -8.51 and a beta of 1.24.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. On average, analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.
Exact Sciences Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
